In August 2016 a Phase I, double-blind, parallel, randomized, placebo-controlled clinical trial was undertaken by the Danish Statens Serum Institut at Hammersmith Hospital in London, UK, in healthy women aged 19–45 years.
The trial aimed to assess the safety and ability to provoke an immune response of the CTH522 chlamydia vaccine.
35 women not infected with chlamydia were included in the trial.
The trial included two adjuvants and a saline control group.
The vaccine was found to be safe, and all women who received the vaccine regardless of adjuvant developed an immune response against chlamydia.The Serum Institute has announced that it will continue to pursue funding to move the vaccine into a Phase II trial.